Estradiol Patch Regret, Stopping, and Restarting: What Patients and Clinicians Need to Know

What the estradiol patch labels say about stopping

The Climara directions start therapy at 0.025 mg per day applied to the skin once weekly, adjust the dose by clinical response, and then say to attempt to taper or discontinue at 3 to 6 month intervals [1]. Vivelle-Dot starts at 0.0375 mg per day applied twice weekly for moderate to severe vasomotor symptoms, with the same instruction to attempt tapering or discontinuation at 3 to 6 month intervals [2]. Vivelle-Dot is given continuously in a woman without an intact uterus and on a cyclic schedule, such as 3 weeks on and 1 week off, in a woman with an intact uterus [2]. Both labels say to reevaluate postmenopausal women periodically to determine whether treatment is still necessary [1][2].

The labels also name one planned situation for stopping: if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of a type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization [1][2].

Switching from oral estrogen to a patch

The Vivelle-Dot dosing section addresses one timing question directly. For women switching from oral estrogens, it says to start the patch 1 week after the oral hormone is withdrawn, or sooner if menopausal symptoms reappear in less than 1 week [2]. That instruction covers a change of route, not resumption after a break from patches.

Delivery background from the Climara label: systemic estradiol availability after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism, and the system delivers estradiol steadily over 7 days [1].

What the patch labels record about side effects

The Climara label reports pooled clinical-trial data in which 614 women were exposed for 3 months. Its table shows dose-related breast pain: 5% at 0.025 mg per day, 8% at 0.05 mg per day and 29% at 0.1 mg per day, against 4% on placebo. Headache was 5%, 18% and 13% versus 10%; abdominal pain 0%, 11% and 16% versus 8%; edema 0.5%, 13% and 10% versus 6% [1]. Reactions the Climara label lists at 10% or more are breast pain, upper respiratory infection, headache, abdominal pain, pain and edema [1].

The Vivelle-Dot label says no clinical trials were conducted with Vivelle-Dot, which it describes as bioequivalent to Vivelle. It lists reactions reported with Vivelle therapy regardless of relationship to treatment, with frequencies for several dose groups. Those listed at 10% or more are headache, breast tenderness, nasopharyngitis, sinusitis, sinus headache, upper respiratory tract infection, back pain, depression, and irregular vaginal bleeding or spotting [2]. Application-site erythema and irritation were observed in 3.2% or less of patients across treatment groups [2]. Climara lists application site reaction among postmarketing reports, where a frequency cannot be reliably estimated [1].

For abnormal bleeding, the Climara label says to perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed, persistent or recurring abnormal genital bleeding [1].

If the reason was fear of cancer or the boxed warning

The boxed warning cites the Women's Health Initiative, which did not test estradiol patches. The estrogen-plus-progestin trial enrolled 16,608 women with a uterus and used oral conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg; hazard ratios were 1.26 for breast cancer, 1.29 for coronary heart disease, 1.41 for stroke and 2.13 for pulmonary embolism [7]. The estrogen-alone trial enrolled 10,739 women with prior hysterectomy on conjugated equine estrogens 0.625 mg; the breast cancer hazard ratio was 0.77 (95% CI 0.59 to 1.01) and stroke 1.39 [8]. Neither trial used transdermal estradiol.

The patch labels say so directly. Their boxed warning states that only daily oral conjugated estrogens 0.625 mg were studied in the WHI estrogen-alone substudy, that the relevance of those findings to lower doses, other routes of administration or other estrogen-alone products is not known, and that the risks cannot be definitively excluded [1].

On 10 November 2025 the FDA asked makers of menopausal hormone therapy to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia, keep the endometrial cancer boxed warning on systemic estrogen-alone products, drop the recommendation to use the lowest effective dose for the shortest time, add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause, and add WHI data for women aged 50 to 59 [9]. The first six revised labels were approved on 12 February 2026: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva [3]. The FDA's list of updated products does not include estradiol patches [4]. The current Climara and Vivelle-Dot labels still carry the older boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [1][2]. Revisions are arriving product by product.

Restarting: contraindications, dose and progestogen

Contraindications apply to any use, including a restart. Climara is contraindicated with undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent neoplasia; active DVT or PE, or a history of either; active arterial thromboembolic disease such as stroke or MI, or a history of it; known anaphylaxis, angioedema or hypersensitivity to the product; hepatic impairment or disease; and protein C, protein S or antithrombin deficiency or other known thrombophilic disorders [1].

On progestogen, the label says that when estrogen is prescribed for a postmenopausal woman with a uterus, adding a progestogen should be considered to reduce the risk of endometrial cancer, and that a woman without a uterus generally does not need one [1]. Unopposed estrogen raises endometrial cancer risk in a woman with a uterus, and adding a progestogen has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer [1].

On dose, for menopausal symptoms the labeled starting dose is 0.025 mg per day once weekly for Climara and 0.0375 mg per day twice weekly for Vivelle-Dot, with later adjustment guided by clinical response. Vivelle-Dot also lists a 0.025 mg per day starting dose for prevention of postmenopausal osteoporosis [1][2]. The Climara label says to place the patch on a clean, dry area of the lower abdomen below the navel or the upper buttock, never on the breasts, and to rotate sites [1].

Clot risk: transdermal versus oral

ESTHER was a French multicenter case-control study of women aged 45 to 70 between 1999 and 2005, with 271 first idiopathic VTE cases and 610 matched controls. The adjusted odds ratio for VTE in current users compared with non-users was 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal estrogen [5]. A BMJ meta-analysis of 8 observational studies and 9 randomized trials found pooled observational odds ratios for a first VTE of 2.5 (1.9 to 3.4) with oral estrogen and 1.2 (0.9 to 1.7) with transdermal, with oral risk highest in the first year at 4.0 (2.9 to 5.7) [6]. These are observational comparisons, not randomized trials of the patch, and the patch labels still carry clot warnings and list active or past DVT or PE as a contraindication [1].

Memory and mood: what estradiol trials found

Neither trial below tested restarting an estradiol patch after a break; both studied starting therapy. ELITE randomized 567 women to oral 17-beta estradiol 1 mg per day or placebo for a mean of about 57 months. The estradiol-minus-placebo difference on verbal memory was -0.06 (95% CI -0.22 to 0.09, p=0.33), with no significant differences in executive function or global cognition, whether therapy began within 6 years of menopause or 10 or more years after [10]. KEEPS-Cog followed 693 recently postmenopausal women for 4 years on oral conjugated equine estrogens 0.45 mg per day or transdermal estradiol 50 mcg per day, each with micronized progesterone 200 mg for 12 days a month, against placebo. There was no treatment-related cognitive benefit; oral conjugated equine estrogens improved depression and anxiety scores, and transdermal estradiol was similar to placebo [11].